Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:58:11.378Z.
Calculation as of: 2026-10-06T17:58:11.378Z.
Quote observation: 2026-10-06T17:55:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$208.37M
EV/EBIT Ratio
N/A
TTM Avg
23.42x
3Y Avg
23.28x
5Y Avg
23.28x
Market Cap
$203.92M
EV/EBIT Ratio
N/A
TTM Avg
6.44x
3Y Avg
6.44x
5Y Avg
6.44x
Market Cap
$211.79M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $206.19M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $206.05M | N/A | 19.40x | 19.40x | 19.40x |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | N/A | 23.42x | 23.28x | 23.28x |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $203.92M | N/A | 6.44x | 6.44x | 6.44x |
| Pro-Dex, Inc. (PDEX)vs › | $208.71M | 16.83x | 15.79x | 14.74x | 15.50x |
| Surrozen, Inc. (SRZN)vs › | $202.26M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | 6.74x | 6.24x | 9.86x | 9.86x |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $200.00M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
